GlassScriptPhysician profile
Jonathan Jasiel Labbe
NPI 1659834042
$1,232.48
in general payments reported to CMS, 2019-2025
12 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.78 · 2023: $242 · 2024: $763 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764 · Travel and Lodging: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.75 |
| Travel and Lodging | $452.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $512.95 | 2024 | Single Use Suction Valve (Sterile) |
| Astrazeneca Pharmaceuticals LP | $210.62 | 2023-2025 | Tezspire, Airsupra, Fasenra |
| Inari Medical, INC. | $141.60 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| United Therapeutics Corporation | $77.25 | 2024-2025 | Tyvaso, Tyvaso |
| Glaxosmithkline, LLC. | $68.22 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Medtronic, INC. | $53.61 | 2024-2025 | Illumisite |
| Merck Sharp & Dohme LLC | $47.22 | 2023 | Recarbrio, Zerbaxa, Dificid |
| Ethicon INC. | $39.79 | 2025 | Monarch Platform |
| Shionogi INC | $38.05 | 2023-2025 | Fetroja |
| Genzyme Corporation | $21.12 | 2024 | |
| Alexion Pharmaceuticals, INC. | $15.78 | 2022 | |
| Zoll Circulation INC | $6.27 | 2024 | Temperature Management System Start-Up Kit, Catheter, Temperature Management System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Labbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.